Ewa Stawowczyk

ORCID: 0009-0003-1446-4607
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Microscopic Colitis
  • Inflammatory Bowel Disease
  • Global Health Care Issues
  • Multiple Sclerosis Research Studies
  • Potassium and Related Disorders
  • Computational Drug Discovery Methods
  • Medication Adherence and Compliance
  • Pharmaceutical industry and healthcare
  • Viral gastroenteritis research and epidemiology
  • Central Venous Catheters and Hemodialysis
  • Chronic Lymphocytic Leukemia Research
  • Electrolyte and hormonal disorders
  • Atrial Fibrillation Management and Outcomes
  • Antibiotic Use and Resistance
  • Adolescent and Pediatric Healthcare
  • Biosimilars and Bioanalytical Methods
  • Intellectual Property and Patents
  • Protein Structure and Dynamics
  • Antibiotics Pharmacokinetics and Efficacy
  • Machine Learning in Bioinformatics
  • Pregnancy and Medication Impact
  • Blood Pressure and Hypertension Studies
  • Membrane-based Ion Separation Techniques

Jagiellonian University
2005-2024

Health Economics and Outcomes Research (United Kingdom)
2023-2024

University of Bielsko-Biała
2018-2019

Indianapolis Zoo
2016

American College of Clinical Pharmacy
2016

University of North Carolina at Pembroke
2016

Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU).To identify different methods for public funding OMPs order to map availability rare disease patients, as well compare expenditures on 8 EU member states.Information reimbursement status 83 was collected countries by distinguishing standard and special reimbursements. In two consecutive years, total were calculated using annual EUR exchange rates. Annual per capita, a proportion GDP,...

10.1186/s13023-018-0927-y article EN cc-by Orphanet Journal of Rare Diseases 2018-10-24

The aim of this study was to review the requirements for reimbursement biosimilars and compare status, market share, costs in selected Central Eastern European (CEE) countries.

10.3389/fphar.2017.00288 article EN cc-by Frontiers in Pharmacology 2017-06-08

A description of many biological processes requires knowledge the 3-D structure proteins and, in particular, defined active site responsible for function. Many proteins, genes which have been identified as result human genome sequencing, and were synthesized experimentally, await identification their activity. Currently used methods do not always yield satisfactory results, new algorithms need to be developed recognize localization sites proteins. This paper describes a computational model...

10.1371/journal.pcbi.0030094 article EN cc-by PLoS Computational Biology 2007-05-23

Objective: To review the reimbursement recommendations issued by selected European health technology assessment agencies for orphan drugs and status of these drugs; to assess relationship between type recommendation status. Methods: The list be included in analysis was obtained from Medicines Agency Orphanet. Seven states were analysis: Belgium, England, France, Germany, Poland, Scotland, Spain. For all identified drugs, relevant data on collected each country. evaluated separately...

10.3389/fphar.2019.01279 article EN cc-by Frontiers in Pharmacology 2019-11-26

Inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn's disease (CD) are chronic autoimmune disorders that constitute a major societal economic burden for individual patients, their families the society. The aim of this study was to assess current prevalence treatment patterns IBD in Poland.We carried out retrospective analysis nationwide databases National Health Fund years from 2012 2014 obtain data on IBD. Patients with were identified according ICD-10 codes...

10.1097/meg.0000000000001047 article EN European Journal of Gastroenterology & Hepatology 2017-12-19

The Act of 12 May 2011 on the Reimbursement Medicines, Foodstuffs Intended for Particular Nutritional Uses and Medical Devices constitutes a major change reimbursement policy in Poland. main aims this were to rationalize reduce spending reimbursed drugs. seems have met these goals: (including pricing drugs) was overhauled expenditure National Health Fund drugs saw significant decrease year following Act's introduction. annual savings achieved since then (mainly due introduction risk sharing...

10.1016/j.healthpol.2016.02.010 article EN cc-by-nc-nd Health Policy 2016-03-08

Zdrowie Publiczne i ZarzÄ dzanie » 2018 Tom 16, Numer 3 Health technology assessment of medical devices A

10.4467/20842627oz.18.021.10434 article EN Zdrowie Publiczne i Zarządzanie 2018-01-01

Until recently, surgery was the only remaining choice for moderate to severe chronic ulcerative colitis patients who failed standard treatment or when it not tolerated. Anti-TNFα is a new, non-invasive option management of colitis. The objective this study assess cost-effectiveness induction and maintenance up 1 year with adalimumab/standard care alone in Poland.A Markov model used estimate expected costs effects alone. For each option, quality adjusted life years were calculated incremental...

10.1007/s00228-016-2103-4 article EN cc-by European Journal of Clinical Pharmacology 2016-08-06

Arterial hypertension is a common disorder that affects around 9 million adults in Poland. Single-pill combinations (SPCs) for the treatment of arterial have significant advantages over free combinations, resulting lower risk cardiovascular events and consumption medical resources. The current ESC/ESH 2013 guidelines first time recommend with combination thiazide-like diuretic calcium channel blocker. Currently, no such reimbursed from public funds Poland.To assess economic value SPC...

10.5603/kp.a2015.0089 article EN cc-by-nc-nd Kardiologia Polska 2015-05-19

To assess the cost-effectiveness of infliximab with standard care (e.g., azathioprine, prednisolone, mesalazine, and 6-mercaptopurine) versus alone for induction maintenance treatment patients ulcerative colitis (UC) in Poland.Cost-utility decision analytic model.A Markov model was used to estimate expected costs effects infliximab/standard alone. For each option, quality-adjusted life-years (QALYs) were calculated incremental cost-utility ratio. The target population consisted a...

10.1002/phar.1742 article EN Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 2016-03-23

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Kawalec P, Stawowczyk E, Mossakowska M, Pilc A. Disease activity, quality of life, and indirect costs ulcerative colitis in Poland. Gastroenterology Review/Przegląd Gastroenterologiczny. 2017;12(1):60-65. doi:10.5114/pg.2017.66324. APA Kawalec, P., Stawowczyk, E., Mossakowska, M., & Pilc, (2017). Gastroenterologiczny, 12(1), 60-65. https://doi.org/10.5114/pg.2017.66324 Chicago Paweł, Ewa Małgorzata Andrzej...

10.5114/pg.2017.66324 article EN cc-by-nc-sa Gastroenterology Review 2017-01-01

Objective The objective of this study was to assess the cost-effectiveness induction and maintenance treatment up 1 year ulcerative colitis with golimumab/standard care standard alone in Poland. Methods A Markov model used estimate expected costs effects a alone. For each option quality adjusted life years were calculated incremental cost-utility ratio. analysis performed from perspective Polish public payer society over 30-years time horizon. clinical parameters derived mainly PURSUIT-SC...

10.1371/journal.pone.0160444 article EN cc-by PLoS ONE 2016-08-05

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Kawalec P, Stawowczyk E. Relationship between physician-based assessment of disease activity, quality life, and costs ulcerative colitis in Poland. Gastroenterology Review/Przegląd Gastroenterologiczny. 2018;13(1):61-68. doi:10.5114/pg.2018.74568. APA Kawalec, P., & Stawowczyk, (2018). Gastroenterologiczny, 13(1), 61-68. https://doi.org/10.5114/pg.2018.74568 Chicago Paweł, Ewa Stawowczyk. 2018. "Relationship...

10.5114/pg.2018.74568 article EN cc-by-nc-sa Gastroenterology Review 2018-01-01

ABSTRACT Objectives: To assess the productivity losses among parents of children with inflammatory bowel diseases (IBDs) in Poland and their relationship disease activity patient's quality life. Methods: A questionnaire‐based self‐reported Internet survey was conducted patients (0‐‐17 years old) a diagnosis ulcerative colitis (UC) or Crohn (CD). Data on indirect direct costs, general patient characteristics, activity, pharmacological treatment, children's life measured Pediatric Quality Life...

10.1097/mpg.0000000000002801 article EN Journal of Pediatric Gastroenterology and Nutrition 2020-05-26

Abstract Background Hyperkalemia (HK) is frequently present in chronic kidney disease (CKD). Risk factors for HK among CKD patients include comorbidities and renin–angiotensin–aldosterone system inhibitor (RAASi) treatment. Current standard of care (SoC) often necessitates RAASi down-titration or discontinuation, resulting poorer cardiorenal outcomes, hospitalization mortality. This study evaluates the cost-effectiveness patiromer with without heart failure (HF) an Italian setting. Methods A...

10.1186/s12962-024-00547-y article EN cc-by Cost Effectiveness and Resource Allocation 2024-05-21

Background: The aim of the study was to characterize procedure peripheral intravenous therapy (IT), including characteristics vascular access and related complications qualitative quantitative analyses drug consumption. Materials Methods: A two-year, retrospective, single-center observational conducted. criterion for a patient in use catheters (PIVCs) upon admission or during stay at internal medicine department (IMD). Results: main reasons hospitalization were exacerbations chronic diseases...

10.3390/antibiotics13070664 article EN cc-by Antibiotics 2024-07-18

Aim: Warfarin and direct-acting oral anticoagulants (DOACs) are widely prescribed to patients with nonvalvular atrial fibrillation (NVAF) reduce risk of stroke systemic embolism (SE). This study aimed assess the cost–effectiveness apixaban compared warfarin, dabigatran rivaroxaban, for NVAF from a US healthcare payer (Medicare) perspective. Methods: A cohort-level Markov model was developed based on previously published model, setting, factoring in anticipated price decreases due market...

10.57264/cer-2024-0163 article EN cc-by-nc-nd Journal of Comparative Effectiveness Research 2024-11-28
Coming Soon ...